Lazard vs PJT Partners
LAZ and PJT side by side, both in services allied with the exchange of securities. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LAZ and PJT compare
Lazard and PJT Partners are about the same size, with market caps of $4.4B and $3.9B.
PJT Partners grew revenue faster over the last twelve months (10.2% versus 9.0% for Lazard).
PJT Partners keeps more of each dollar of sales as profit, with a net margin of 10.5% compared with 5.5% at Lazard.
Both pay dividends: Lazard yields 3.7% and PJT Partners 0.66%.
PJT Partners scores higher on the StockData Score (16 against 5 for Lazard), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LAZ | PJT |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $3.9B |
| Share price | $40.40 | $150.90 |
| Change, 1 year | −22.2% | −11.5% |
| Change, 5 years | −12.7% | 85.2% |
| Beta (5Y) | 1.40 | 0.85 |
| Employees | 3,309 | 1,224 |
| StockData Score | ||
| Total score | 5 | 16 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 24.5× | – |
| P/S | 1.3× (better) | 2.1× |
| P/B | 4.7× (better) | 10.6× |
| EV/EBITDA | 10.6× (better) | 11.0× |
| P/FCF | 6.5× | 5.6× (better) |
| FCF yield | 15.4% | 17.8% (better) |
| Fair value | $35.79 | $195.80 |
| Margin of safety | −12.9% | 22.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.0% | 10.2% (better) |
| Revenue growth, 5Y average | 3.8% | 10.2% (better) |
| Net income growth (TTM) | −32.4% | 7.6% (better) |
| EPS growth (TTM) | −34.5% | – |
| EPS growth, 5Y average | −9.3% | – |
| Profitability | ||
| Operating margin | 7.9% | – |
| Net margin | 5.5% | 10.5% (better) |
| FCF margin | 20.3% | 37.7% (better) |
| Return on equity | 20.6% | 64.6% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 3.0× | – |
| Altman Z-score | 2.15 | 3.92 (better) |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Dividend yield | 3.7% (better) | 0.66% |
| Payout ratio | 104% | 13.3% |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | 1.2% | – |
| Buyback yield | 3.0% | 3.6% (better) |
| Shareholder yield | 6.8% (better) | 4.3% |
| Ownership | ||
| Held by institutions | 92.5% | 89.2% |
| Held by insiders | 4.9% | 2.7% |
| Insider net buying, 12 months | −$8.7M | −$3.7M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.4% | 7.3% |
Go deeper
- LAZ stock overview
- LAZ income statement
- LAZ valuation and score
- PJT stock overview
- PJT income statement
- PJT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.